WO2003087320A3 - Antagonists of il-21 and modulation of il-21-mediated t cell responses - Google Patents

Antagonists of il-21 and modulation of il-21-mediated t cell responses Download PDF

Info

Publication number
WO2003087320A3
WO2003087320A3 PCT/US2003/010736 US0310736W WO03087320A3 WO 2003087320 A3 WO2003087320 A3 WO 2003087320A3 US 0310736 W US0310736 W US 0310736W WO 03087320 A3 WO03087320 A3 WO 03087320A3
Authority
WO
WIPO (PCT)
Prior art keywords
mil
antagonists
polypeptide
mutant
joined
Prior art date
Application number
PCT/US2003/010736
Other languages
French (fr)
Other versions
WO2003087320A2 (en
Inventor
Thomas Moll
Terry B Strom
Xin Xiao Zheng
Original Assignee
Beth Israel Hospital
Thomas Moll
Terry B Strom
Xin Xiao Zheng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Thomas Moll, Terry B Strom, Xin Xiao Zheng filed Critical Beth Israel Hospital
Priority to AU2003230834A priority Critical patent/AU2003230834A1/en
Publication of WO2003087320A2 publication Critical patent/WO2003087320A2/en
Publication of WO2003087320A3 publication Critical patent/WO2003087320A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention is based, in part, on the creation of molecules that antagonize the receptor for interleukin-21 (IL-21). The antagonist can be, for example, a mutant of IL-21 (mIL-21). Moreover, the mIL-21 polypeptide can be joined to (e.g., joined by way of a peptide bond to) a heterologous polypeptide (i.e., a non-IL-21 polypeptide), such as an Fc region of an immunoglobulin molecule ('mIL-21/Fc'). Such antagonists have been shown to inhibit cellular proliferation in response to either anti-CD3 monoclonal antibodies or anti-CD3 antibodies applied together with IL-2, IL-15, or either cytokine (IL-2 or IL-15) together with IL-21 (these studies and their significance are described further below). Accordingly, the present invention features polypeptides that include a mutant IL-21 sequence, nucleic acids encoding those mutants, compositions containing them, and methods of using them in a variety of diagnostic, prognostic, and treatment regimes.
PCT/US2003/010736 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses WO2003087320A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003230834A AU2003230834A1 (en) 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37103802P 2002-04-09 2002-04-09
US60/371,038 2002-04-09

Publications (2)

Publication Number Publication Date
WO2003087320A2 WO2003087320A2 (en) 2003-10-23
WO2003087320A3 true WO2003087320A3 (en) 2004-08-26

Family

ID=29250623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010736 WO2003087320A2 (en) 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses

Country Status (2)

Country Link
AU (1) AU2003230834A1 (en)
WO (1) WO2003087320A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444363T1 (en) 2001-11-05 2009-10-15 Zymogenetics Inc IL-21 ANTAGONISTS
ES2381265T3 (en) 2002-06-07 2012-05-24 Zymogenetics, Inc. Use of IL-21 and monoclonal antibody to treat solid cancers
US20060177421A1 (en) * 2002-10-11 2006-08-10 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
PL376118A1 (en) * 2002-10-11 2005-12-12 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
ATE448298T1 (en) 2002-12-13 2009-11-15 Zymogenetics Inc IL-21 PRODUCTION IN PROKARYONTIC HOSTS
CA2542179A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
JP2007522109A (en) * 2004-01-15 2007-08-09 ノボ　ノルディスク　アクティーゼルスカブ Treatment of autoimmune disease and allograft rejection with IL-21
EP1586585A1 (en) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expression system for the production of IL-15/Fc fusion proteins and their use
AR051071A1 (en) * 2004-08-05 2006-12-20 Wyeth Corp ANTAGONISM OF THE ACTIVITY OF THE INTERLEUQUINA RECEIVER-21
ITRM20040586A1 (en) * 2004-11-29 2005-02-28 Giuliani Spa ANTIGENIC EPITOPES OF INTERLEUCHINA-21, RELATIVE ANTIBODIES AND THEIR USE IN MEDICAL FIELD.
GT200600148A (en) 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
JP2008538290A (en) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ IL-21 mutant
ES2409835T3 (en) 2005-11-28 2013-06-28 Zymogenetics, Inc. IL-21 antagonists
AU2006341398B9 (en) 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CA2671665A1 (en) * 2006-12-21 2008-06-26 Novo-Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
CA2707026C (en) 2007-12-07 2017-04-11 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
EP2406282A1 (en) * 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
CN102071192A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA used for curing psoriasis
CN102071191A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA for treating psoriasis
CN102071198A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA for treating psoriasis
ES2778053T3 (en) * 2011-01-18 2020-08-07 Bioniz Llc Compositions to modulate gamma-c cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
CN105198999A (en) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 Fusion protein and its preparation method and use
KR102370727B1 (en) 2015-10-09 2022-03-04 바이오니즈, 엘엘씨 Synthetic peptide inhibiting gamma-C-cytokine activity and kit using same
KR101928981B1 (en) * 2016-09-02 2018-12-13 고려대학교 산학협력단 Heterodimeric Fc-fused IL-21 and Pharmaceutical Composition Comprising the Same
CN111205361B (en) * 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 Interleukin 21 protein (IL21) mutant and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARRISH-NOVAK ET AL: "Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function", NATURE, vol. 408, 2 November 2000 (2000-11-02), pages 57 - 63, XP002186602 *

Also Published As

Publication number Publication date
AU2003230834A8 (en) 2003-10-27
AU2003230834A1 (en) 2003-10-27
WO2003087320A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
WO2003087320A3 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
RU2312677C9 (en) Immunocytokines possessing modulated selectivity
CA2312188A1 (en) Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
DE122007000078I2 (en) CTL4A receptor, fusion proteins containing it and their use
ATE350386T1 (en) ELK LIGAND, A CYTOKINE
DE69638355D1 (en) Anti-CD3 antibodies for use in inducing immunosuppression
AU6238698A (en) Tumor necrosis factor receptor 5
HK1080511A1 (en) Il-1 receptor based antagonists and methods of making and using
IL100731A0 (en) Mixed specificity fusion protein and pharmaceutical composition containing it
IL108374A0 (en) Methods and compositions for regulating the immune response using ctla4-binding molecules and il4-binding molecules
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
CA2253239A1 (en) Antibodies against interferon alpha/beta receptor
Benjamin et al. Heterogeneity in interleukin (IL)-1 receptors expressed on human B cell lines. Differences in the molecular properties of IL-1 alpha and IL-1 beta binding sites.
DK0920509T3 (en) Polypeptides capable of forming antigen binding structures with specificity for Rhesus D antigens, their encoding DNA, and their method of preparation and use thereof
TW272197B (en)
Liparoto et al. Biosensor analysis of the interleukin‐2 receptor complex
Renné et al. A new type of cytokine receptor antagonist directly targeting gp130
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
Keegan et al. The IL-4 receptor: biochemical characterization of IL-4-binding molecules in a T cell line expressing large numbers of receptors.
Balasubramanian et al. Ligand binding kinetics of IL-2 and IL-15 to heteromers formed by extracellular domains of the three IL-2 receptor subunits
Pletnev et al. A model of the ternary complex of interleukin-10 with its soluble receptors
AU2021278998A8 (en) Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
Suzuki et al. IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibody
CA2133873A1 (en) Tnf inhibitors
Baran et al. Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP